BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG

Kyle LaHucik / Endpoints News

BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG

BrainChild Bio raised $116 million in a Series A to fund a pivotal trial of a B7-H3–targeted CAR-T therapy for pediatric diffuse intrinsic pontine glioma (DIPG), aiming to make CAR-Ts function more like small molecules for brain tumors.

SSteven Brugger MMichael Jensen

BBrainChild Bio

More: FinSMEs, Fierce Biotech

FinSMEs: BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
Fierce Biotech / Darren Incorvaia: BrainChild Bio raises $116M Series A from Seattle Children’s and WRF to fund pivotal CAR-T trial for DIPG

Comments: Kyle LaHucik, Alex Philippidis

Kyle LaHucik BrainChild Bio, a Seattle Children's spinout creating CAR-T therapies for brain tumors in both children and adults, has collected $116 million to get into pivotal testing...

Alex Philippidis 8September: How does BrainChild Bio plan to stand out among drug developers targeting #cancer tumors within the CNS? Read insights from CEO Steven Brugger and founder/CSO...

No comments yet.